Today, Integral Biosciences Pvt Ltd (IBS) and Monash University (Monash) have announced a research collaboration to discover small molecule therapeutics.
NEWS PROVIDED BY
Integral Biosciences Pvt Ltd
Today, Integral Biosciences Pvt Ltd (IBS) and Monash University (Monash) have announced a research collaboration to discover small molecule therapeutics.
The partnership will leverage the research strengths of Monash and IBS to initially focus on the design, synthesis and evaluation of novel compounds that inhibit an epigenetic enzyme with the potential application in the treatment of a range of cancers.
The collaboration is being led by medicinal chemist Professor Jonathan Baell from the Monash Institute of Pharmaceutical Sciences (MIPS) alongside Dr Brahmam Pujala from IBS. Monash and IBS are also exploring the potential to work together on other drug discovery projects.
Commenting on this collaboration, Dr. Pujala, said “Monash is one of the top-ranked academic institutions in Australia and we at IBS are delighted to be able to partner with them on this exciting venture. This partnership with Monash aligns our joint vision of discovering small molecules that will benefit a broad population of cancer patients. We look forward to working with the accomplished Monash team to identify candidate medicines.
Commenting on this collaboration, Professor Baell said “Advancing early drug discovery projects along the development pipeline face a number of challenges and therefore collaboration is crucial to success. We are delighted to be partnering with IBS to progress a number of early drug discovery projects. IBS is an integrated drug discovery incubator with a successful track record of more than a decade and we are very much looking forward to joining forces and welcoming IBS on board as an extension of our team at MIPS.”
About Integral BioSciences Pvt Ltd:-
IBS, an integrated drug discovery incubator, has presence in Noida, India. It has integrated drug discovery expertise with a track record of working over 30 programs, in multiple therapeutic areas including Oncology, Immuno-oncology, CNS, Metabolic Disorder and Rare Diseases, in its presence of over a decade. It has successful collaboration with companies present in different parts of the world, with flexible business model. For more info: www.integralbiosciences.com
About the Monash Institute of Pharmaceutical Sciences (MIPS)
The Monash Institute of Pharmaceutical Sciences is a dynamic, innovative and ambitious research institute, comprising over 400 scientists engaged in research in drug discovery, design, delivery and use. As part of the top ranked Pharmacy faculty in the Asia Pacific, MIPS’ therapeutic strengths lie in neuroscience and mental health, cardiovascular and metabolic health and global health. The team at MIPS is committed to research translation and have made major contributions to collaborative drug discovery programs that have progressed more than 30 novel drug candidates into clinical development. To learn more visit: https://www.monash.edu/pharm/research